1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Lenvatinib for advanced grade 1/2 pancreatic and GI neuroendocrine tumors

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Protocol: Lenvatinib for advanced grade 1/2 pancreatic and GI neuroendocrine tumors

New Protocol: Lenvatinib for advanced grade 1/2 pancreatic and GI neuroendocrine tumors
Study:
  • Open-label phase II trial (TALENT)
  • Advanced pancreatic (panNET) or gastrointestinal (GI-NET), grade 1/2 neuroendocrine tumor progressed on a targeted agent (pancreatic) or somatostatic analog (GI)
  • Lenvatinib 24 mg PO daily until progression in panNET (n=55) and GI-NET (n=56)
Efficacy:
  • ORR: 44.2% in panNET and 16.4% in GI-NET
  • Median DoR: 19.9 mos in panNET and 33.9 mos in GI-NET
  • Median PFS: 15.6 mos in panNET and 15.7 mos in GI-NET
Safety:
  • Grade >=3 AEs: hypertension (22%), diarrhea (11%), asthenia (11%), vomiting (5%), PPE (4%)

J Clin Oncol. Published online on May 4, 2021

Capdevial J, et al. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

https://doi.org/10.1200/JCO.20.03368

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More